A new study provides estimates on how much longer people with mild cognitive decline due to Alzheimer's disease might live independently after starting newer medications like lecanemab or donanemab. While these drugs can clear amyloid plaques from the brain, they also come with risks and high costs. The study aims to help patients and doctors make informed decisions about treatment by quantifying the potential benefits.
Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease. Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that are the hallmark of Alzheimer’s. Both drugs require time-consuming biweekly or monthly infusions, however, and carry the risk of life-threatening swelling or bleeding in the brain.
Then there’s the expense — even on Medicare, co-pays for the year can be thousands of dollars. Are these downsides worth the risk? You may decide the answer is yes if you knew how much longer you might live independently, said Dr. Sarah Hartz, a professor of psychiatry at the Washington University School of Medicine in St. Louis. She is the lead author of a new study that estimated the amount of time people might continue to perform daily activities without assistance after beginning lecanemab, marketed as Leqembi, or donanemab, marketed as Kisunla. “Patients want to know how long a drug will allow them to keep driving, pay their own bills, cook at home and dress themselves,” Hartz said. Calculations ranged from eight months to an additional 39 months of independent living, depending on the severity of the disease when medication was started. “We wouldn’t want people to count on these numbers as definitive, however, because it’s just an estimate and depends on the person and where they are at in their cognitive decline,” Hartz said. “Instead, they should use these estimates to structure a conversation with their doctor about going on the medication: ‘OK, is this right for me or not?’”Using language that is meaningful to patients when discussing disease prognosis is a huge benefit for both clinicians and patients, said neurologist Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases in Boca Raton, Florida. He was not involved in the study. “However, these are not miracle drugs, so please keep that in mind,” Isaacson said. “All that happens is that people get less worse over time — instead of declining by three years, they decline by two years.” Estimating ability to live without assistance The study, published Thursday in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions, analyzed Washington University data on the natural progression of Alzheimer’s disease in 282 patients who had not been treated with medication. “We looked at four different specific functions: Could the person pay their bills, drive a car, manage their own calendar and medications, and prepare their own meals?” Hartz said. “We defined the loss of independent living as needing assistance on at least three of those.” The amount of time untreated patients spent living independently was used to create a timetable of decline. That trajectory was then compared with what was seen in patients using lecanemab and donanemab during each drug’s clinical trial. A person with typical mild cognitive decline, such as forgetting appointments or being unable to follow conversations fully, could expect to live independently for 29 months without treatment, the analysis showed. Taking donanemab added eight months of independence, while taking lecanemab added 10 months, according to the calculations. While those additional months may not appear to be a long extension of independence, the estimates could be meaningful for some people, Hartz said. “The drugs are very expensive, but once you compare that to the cost of a residential care facility or a nursing home, you might have a different perspective,” she said. People with mild but obvious symptoms — such as repeating the same questions or getting lost — who already live in a residential facility also want to know when they will need additional, more expensive care, Hartz said. At this stage of the disease, researchers estimated donanemab provided an additional 19 months of being able to dress, eat and bathe independently. Lecanemab provided 26 additional months of self-care. “I want to stress that the purpose of this study was not to advocate for or against these medications,” Hartz said. “The purpose of the paper is to put the impact of these medications into context in ways that can help people make the decisions that are best for themselves and their family members.” However, the analysis used in the study assumed changes in dementia scores “are linear and can be equated to changes in months of life. This has never been validated,” said Dr. Alberto Espay, a professor of neurology at the University of Cincinnati and director and research endowed chair of the university’s Gardner Family Center for Parkinson’s Disease and Movement Disorders. “Further, ‘extension of independence’ means statistically longer time in the same state before further decline, not statistical improvement,” Espay said in an email.
ALZHEIMER's DISEASE MEDICATIONS LECANEMAB DONANEMAB INDEPENDENT LIVING COGNITIVE DECLINE
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Updated Alzheimer's Disease Evaluation Guidelines Released by the Alzheimer's AssociationThe Alzheimer's Association has issued new clinical practice guidelines for evaluating individuals suspected of having Alzheimer's disease (AD) or AD-related neurodegenerative disorders. These guidelines provide updated recommendations for both primary and specialty care settings, marking the first update for specialists since 2001 and the introduction of guidelines for primary care physicians.
Read more »
Alzheimer’s Caregivers Share How to Care for Someone With Alzheimer’sLearn tips on how to care for a loved one with Alzheimer’s from people who have been there themselves.
Read more »
Florida Woman Arrested Again With Drugs in 'Definitely Not a Bag Full of Drugs'Teryn Acri of Florida has been arrested twice in two weeks for drug possession. The Brevard County Sheriff's Office made the arrests after discovering drugs in Acri's possession during separate traffic stops.
Read more »
Bag labeled 'Definitely Not A Bag Full Of Drugs' found full of drugs in Central FloridaA Florida woman was arrested for the second time in less than two weeks after deputies discovered drugs in a bag labeled 'Definitely Not A Bag Full Of Drugs.'
Read more »
Misdiagnosis of LATE Dementia as Alzheimer's Highlights Need for Objective CriteriaA new report published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association emphasizes the urgent need for 'objective criteria' to diagnose and stage various dementia types, including LATE (limbic-predominant age-related TDP-43 encephalopathy). LATE, often mistaken for Alzheimer's, is characterized by changes in the TDP-43 protein in brain tissue and frequently coexists with Alzheimer's disease pathologies. The proposed criteria aim to improve clinical differentiation between LATE and Alzheimer's, leading to more accurate diagnoses and tailored treatment strategies.
Read more »
Xenon gas could protect against Alzheimer's disease: Mouse studyMost treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- approach: using Xenon gas.
Read more »